Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850641 | 0.98 | KCNH2 (0.50) | KCNH2ALDH1A1CYP19A1SLC5A2MIF | |
| SCHEMBL8551658 | 0.98 | KCNH2 (0.50) | KCNH2ALDH1A1CYP19A1SLC5A2MIF | |
| SCHEMBL9215468 | 0.94 | ALDH1A1 (0.46) | KCNH2ALDH1A1CYP19A1SLC5A2MIF | |
| SCHEMBL3182612 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP19A1SLC5A2GABRA2GABRB2 | |
| SCHEMBL22941955 | 0.85 | KCNH2 (0.61) | KCNH2ALDH1A1CYP19A1MIFTDP1 | |
| SCHEMBL12356537 | 0.83 | KCNH2 (0.59) | KCNH2ALDH1A1CYP19A1MIFKDM4E | |
| SCHEMBL25801711 | 0.80 | KCNH2 (0.52) | KCNH2ALDH1A1CYP19A1SLC5A2MIF | |
| SCHEMBL14722461 | 0.78 | KCNH2 (0.48) | KCNH2ALDH1A1CYP19A1MIFCNR2 | |
| SCHEMBL4592210 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SLC5A2 | |
| SCHEMBL10843908 | 0.77 | CYP1A2 (0.38) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0114770-B1 | COMPOUNDS WITH DINITROGEN CONTAINING HETEROCYCLIC NUCLEUS, THEIR PROCESS OF PREPARATION AND MEDICINES ACTIVE ON THE CENTRAL NERVE SYSTEM CONTAINING THEM | SANOFI S.A. (FR) | 1987-07-22 | — | — | EP | claimed |
| EP-0114770-A2 | Compounds with dinitrogen containing heterocyclic nucleus, their process of preparation and medicines active on the central nerve system containing them | SANOFI S.A. (FR) | 1984-08-01 | — | — | EP | claimed |
| WO-2013054302-A1 | METHOD FOR PREPARING TRIARYL(HETEROARYL)BISMUTHS, AND USES THEREOF FOR THE SYNTHESIS OF AROMATIC OR HETEROAROMATIC DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-04-18 | — | — | WO | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
| US-5449676-A | Bronchodilator agents | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-09-12 | — | — | US | disclosed |
| US-5236918-A | Bronchial disorders | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1993-08-17 | — | — | US | disclosed |
| WO-1992019602-A1 | NOVEL PYRIDAZINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-11-12 | — | — | WO | disclosed |
| EP-0510562-A1 | Pyridazines | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1992-10-28 | — | — | EP | disclosed |
| WO-1990012789-A1 | NOVEL ARYLPYRIDAZINES, THEIR MANUFACTURE, USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1990-11-01 | — | — | WO | disclosed |
| EP-0393500-A1 | Arylpyridazines, their preparation, their use and pharmaceuticals containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1990-10-24 | — | — | EP | disclosed |
| US-4624952-A | Pyridazine and pyrimidine compounds active on the central nervous system as sedatives or anticonvulsants | SANOFI (FR) | 1986-11-25 | — | — | US | disclosed |
| US-4595521-A | In liquid crystalline carrier | HOFFMANN-LA ROCHE INC. (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0111695-A2 | Pyridazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-06-27 | — | — | EP | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | KCNH2 340/4885ALDH1A1 584/4885CYP19A1 779/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | KCNH2 765/4885ALDH1A1 272/4885CYP19A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.